AIM IMMUNOTECH INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $21K | ↓-53.3% | — | — | — |
| 2025-09-30 | $26K | ↓-25.7% | $-3M | ↑+11.2% | -9411.5% |
| 2025-06-30 | $25K | ↓-50.0% | $-3M | ↓-52.2% | -10584.0% |
| 2025-03-31 | $16K | ↓-60.0% | $-4M | ↑+36.3% | -22618.8% |
| 2024-12-31 | $45K | ↓-30.8% | — | — | — |
| 2024-09-30 | $35K | ↓-23.9% | $-4M | ↑+52.7% | -12825.7% |
| 2024-06-30 | $50K | ↑+19.0% | $-2M | ↑+62.6% | -7388.0% |
| 2024-03-31 | $40K | ↓-18.4% | $-6M | ↓-58.9% | -14335.0% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$21K
↓-53.3% -$24K YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
AIM Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyAIM Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics